ANEW MEDICAL Awarded European Patent for Human Klotho Gene RNA Slice Variant and Protein

June 26, 2024

DENVER, Colo., Jun 26, 2024 (247marketnews.com)- ANEW MEDICAL, INC. (NASDAQ:WENA) was awarded European patent EP3377091B1, for the use of ANEW’s secreted Klotho gene sequence and gene delivery systems to be used in the treatment of diminished cognition, memory loss, dementia and other neurodegenerative diseases.

ANEW MEDICAL’s Founder and CEO, Dr. Joseph Sinkule, stated, “We feel strongly about the significant potential of this therapy and have taken meticulous steps to protect and expand our licensed intellectual property in major global markets. These assets play a vital role in our international product development efforts for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and ALS (Lou Gehrig’s disease). We believe our secreted Klotho RNA splice variant (“s-KL”) programs for cell and gene therapy, along with the related protein and genomics diagnostic programs, represent a groundbreaking approach to identifying and treating these devastating diseases.

“There are two proteins transcribed from the human Klotho gene, s-KL is the RNA splice variant made from the gene. It differs from the full-length Klotho protein transcribed from the gene as it is made by cells primarily in the kidneys and controls phosphate and calcium ion homeostasis in the body. Our studies show that s-KL protein is made predominantly by cells in the human brain and is extremely important in brain function and in the maintenance of normal neurologic function throughout the central nervous system (CNS) and peripheral nervous system. As we advance the program, ANEW will explore diagnostics and therapeutics utilizing the s-KL protein and its interactions with other human proteins and ‘genes of interest.’ We will also pursue other medical product development and commercial opportunities.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (WENA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.